During the Barclays 30th Annual Leveraged Finance Conference held on May 19, 2026, Bausch Health Companies Inc. (BHC) showcased its strong financial performance, reporting 12 consecutive quarters of growth in both revenue and EBITDA. Company executives William Woodfield, Senior VP & Treasurer, and Garen Sarafian, VP & Head of Investor Relations, highlighted the strategic focus on enhancing top line growth and cash flow management as key drivers of this success. The Salix and Xifaxan business segments, along with international operations, have significantly contributed to this positive trend. Woodfield emphasized their commitment to sustaining this growth momentum moving forward, indicating confidence in the company's operational strategies and market positioning. The executives' insights reflect a robust outlook for Bausch Health as they continue to navigate the competitive healthcare landscape.